Antiangiogeneettinen hoito lapsipotilailla, joilla on pahanlaatuinen kasvai

Conditions: Pediatric malignancies with no conventional treatment modalities left
Therapeutic area: Body processes [G] - Biological Phenomena [G16]

Registration Number: EUCTR2008-006989-28-FI

Lead Sponsor: HUCH, Hospital for Children and Adolescents

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Authorised-recruitment may be ongoing or finished

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

Pediatric malignancies with no conventional treatment modalities left
Age 1-18 year
Are the trial subjects under 18? yes
Number of subjects for this age range: 20
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Decline in consciousness, inability to swallow, need of opioids for pain

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Secondary Objective: Not applicable;Primary end point(s): - overall survival of pediatric patients with malignancies without conventional treatment modalities left<br>- the quality of life in pediatric patients with malignancies without conventional treatment modalities left<br>- the possible adverse effects of this combination therapy;Timepoint(s) of evaluation of this end point: every 3 months;Main Objective: In the present research protocol we are proposing a phase II clinical trial for therapy of pediatric patients with malignancies without conventional treatment modalities left. Our aim is to explore whether the combination of thalidomide, celecoxib and etoposide would prolong survival and/or improve the quality of life in pediatric patients with malignancies without conventional treatment modalities left. The possible adverse effects of this combination therapy will be registered.

Secondary Outcome Measures